Charles Schwab Investment Management Inc. Grows Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Charles Schwab Investment Management Inc. increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,812,502 shares of the company's stock after acquiring an additional 45,090 shares during the period. Charles Schwab Investment Management Inc. owned about 0.39% of Roivant Sciences worth $33,272,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences in the 3rd quarter worth $46,333,000. FMR LLC increased its holdings in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Geode Capital Management LLC raised its position in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock worth $89,400,000 after buying an additional 1,460,205 shares during the last quarter. State Street Corp lifted its stake in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after acquiring an additional 1,118,561 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock valued at $26,625,000 after acquiring an additional 762,953 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Roivant Sciences currently has a consensus rating of "Buy" and an average target price of $18.08.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the sale, the chief operating officer now owns 595,580 shares in the company, valued at approximately $6,843,214.20. This trade represents a 14.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,975,586 shares of company stock valued at $22,640,661 over the last 90 days. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV traded up $0.03 during midday trading on Thursday, hitting $10.97. The company had a trading volume of 10,312,742 shares, compared to its average volume of 5,565,394. The company has a market cap of $7.82 billion, a price-to-earnings ratio of -72.96 and a beta of 1.26. The company has a fifty day moving average of $10.78 and a two-hundred day moving average of $11.48. Roivant Sciences Ltd. has a 12-month low of $9.80 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.